



ATTORNEY DOCKET NO. 22000.0106U2  
PATENT

64 5164  
#8  
BP  
6-27-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Brigham et al.

Serial No.: 10/027,797

Filed: December 20, 2001

For: GENE DELIVERY AND EXPRESSION IN  
AREAS INACCESSIBLE TO DIRECT  
PROTEIN DELIVERY

Group Art Unit: 3764

Examiner: Unassigned

**RECEIVED**

JUN 19 2002

TECH CENTER 1600/2900

TECHNOLOGY CENTER R3700

JUN 12 2002

RECEIVED

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811

May 16, 2002

Sir:


Submitted herewith on Form PTO-1449 is a listing of documents known to applicants and/or their attorneys/agents in compliance with the requirement of 37 C.F.R. § 1.56. Each of the cited documents was previously listed on Form PTO-1449 and submitted by applicants or cited by the Examiner on Form PTO-892 in the parent application (U.S. Serial No. 08/951,552, filed October 16, 1997, now U.S. Patent No. 6,365,575). Therefore, copies of the cited documents are not provided herewith.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

It is believed that this Information Disclosure Statement is being timely filed in accordance with 37 C.F.R. § 1.97(b)(3), i.e., before the mailing date of the first Office Action on the merits regarding the above-referenced application; therefore, it is believed that no fee is due. However, the Commissioner is hereby authorized to charge any fee that may be required, or to credit any overpayment, to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.




Shari J. Corin, Ph.D.  
Registration No. 46,243

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811  
404-688-0770

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

  
Shari J. Corin, Ph.D.

May 16, 2002  
Date



OFFICE OF  
COMMERCE

ATTORNEY DOCKET NO. 22000.0106U2  
SERIAL NO. 10/027,797  
Page 1 of 1

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO.: 22000.0106U2		SERIAL NO. 10/027,797			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Brigham et al.					
		FILING DATE: December 20, 2001		GROUP: 3764			
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,364,791	11/15/94	Vegeto et al.			
	A2	5,676,954	10/14/97	Brigham			
	A3	5,756,353	5/26/98	Debs			
FOREIGN PATENT DOCUMENTS							
	A4	92/19730	12.11.92	WO/PCT			
	A5	93/12240	24.06.93	WO/PCT			
	A6	93/12756	08.07.93	WO/PCT			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A7	Bedard, M. et al., "Release of Interleukin-8, Interleukin-6, and Colony-stimulating Factors by Upper Airway Epithelial Cells: Implications for Cystic Fibrosis," <i>Am. J. Respir. Cell Mol. Biol.</i> , 9:455-462 (1993)					
	A8	Boat, T.F. et al., "Cystic Fibrosis," <i>The Metabolic Basis of Inherited Disease</i> , 2649-2680 (1989)					
	A9	Brigham, K. et al., "Gene Therapy in Acute Critical Illness," <i>New Horizons</i> 3(2):321-329 (1995)					
	A10	Campbell, E.J. et al., "Pericellular Proteolysis by Neutrophils in the Presence of Proteinase Inhibitors: Effects of Substrate Opsonization," <i>J. Cell Biol.</i> 106:667-676 (1988)					
	A11	Canonico, A.E. et al., "Plasmid-Liposome Transfer of the $\alpha_1$ Antitrypsin Gene to Cystic Fibrosis Bronchial Epithelial Cells Prevents Elastase-induced Cell Detachment and Cytokine Release," <i>Am. J. Respir. Cell. Mol. Biol.</i> 14:348-355 (1996)					
	A12	Canonico, A. et al., "Aerosol and Intravenous Transfection of Human $\alpha_1$ -Antitrypsin Gene to Lungs of Rabbits," <i>Am. J. Respir. Cell Mol. Biol.</i> 10:24-29 (1994)					
	A13	Canonico et al., "No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes," <i>J. Applied Physiol.</i> 77:415-419 (1994)					
	A14	Cantin, A.M. et al., "Antineutrophil Elastase Activity in Cystic Fibrosis Serum," <i>Pediatr. Pulmonol.</i> 11:249-253 (1991)					
	A15	Conary et al., "Protection of Rabbit Lungs from Endotoxin Injury by In Vivo Hyperexpression of the Prostaglandin G/H Synthase Gene," <i>J. Clin. Invest.</i> 93:1834-1840 (1994)					
	A16	Cozens, A.L. et al., "Characterization of Immortal Cystic Fibrosis Tracheobronchial Gland Epithelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:5171-5175 (1992)					
	A17	Falk, W. et al., "A 48-Well Micro Chemotaxis Assembly for Rapid and Accurate Measurement of Leukocyte Migration," <i>J. Immunol. Methods</i> 33:239-247 (1980)					
	A18	Hubbard, R.C. et al., "Fate of Aerosolized Recombinant DNA-Produced $\alpha_1$ - antitrypsin: Use of the Epithelial Surface of the Lower Respiratory Tract to Administer Proteins of Therapeutic Importance," <i>Proc. Natl. Acad. Sci. USA</i> 86:680-684 (1989)					
	A19	Johnson, "Gen Therapy for Cystic Fibrosis," <i>Chest</i> . 107:77S-83S (1995)					



COPY OF PAPERS  
ORIGINAL FILED

TORNEY DOCKET NO. 22000.0106U2  
SERIAL NO. 10/027,797  
Page 2 of 1

A20	Kay et al., "In Vivo Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993)
A21	Korst et al., "Gene therapy for the Respiratory Manifestations of Cystic Fibrosis," <i>Am. J. Respir. Crit. Care Med.</i> 151:575-587 (1995)
A22	McCain, R. et al., "Granulocyte/Macrophage Colony-stimulating Factor Stimulates Human Polymorphonuclear Leukocytes to Produce Interleukin-8 <i>In Vitro</i> ," <i>Am. J. Respir. Cell Mol. Biol.</i> 8:28-34 (1993)
A23	McElvaney, N.G. et al., "Aerosol $\alpha$ 1-Antitrypsin Treatment for Cystic Fibrosis," <i>Lancet</i> 337:392-394 (1991)
A24	McElvaney, N.G. et al., "Modulation of Airway Inflammation in Cystic Fibrosis," <i>J. Clin. Invest.</i> 90:1296-1301 (1992)
A25	Meyer, K.C. et al., "Studies of Bronchoalveolar Lavage Cells and Fluids in Pulmonary Sarcoidosis," <i>Am. Rev. Resp. Disease</i> 140:1446-1449 (1989)
A26	Nakamura, H. et al., "Neutrophil Elastase in Respiratory Epithelial Lining Fluid of Individuals with Cystic Fibrosis Induces Interleukin-8 Gene Expression in a Human Bronchial Epithelial Cell Line," <i>J. Clin. Invest.</i> 89:1478-1484 (1992)
A27	Orkin et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," 1-41 (1995)
A28	Persmark, M. et al., "Inhibition of Respiratory Syncytial Virus (RSV) Infectivity by Liposome-Mediated Antiprotease Gene Transfer," <i>J. Invest. Med.</i> 43 S:220A (1995)
A29	Richman-Eisenstat, J.B.Y. et al., "Interleukin-8: an Important Chemoattractant in Sputum of Patients with Chronic Inflammatory Airway Diseases," <i>Am. J. Phys.</i> 264:L413-L418 (1993)
A30	Ruef, C. et al., "Regulation of Cytokine Secretion by Cystic Fibrosis Airway Epithelial Cells," <i>Eur. Respir. J.</i> 6:1429-1436 (1993)
A31	Suter, S. et al., "Levels of Free Granulocyte Elastase in Bronchial Secretions from Patients with Cystic Fibrosis: Effect of Antimicrobial Treatment Against <i>Pseudomonas Aeruginosa</i> ," <i>J. Infect. Dis.</i> 153:902-909 (1986)
A32	Suter, S. et al., "Proteolytic Inactivation of $\alpha$ <sub>1</sub> -Proteinase Inhibitor in Infected Bronchial Secretions from Patients with Cystic Fibrosis," <i>Eur. Respir. J.</i> 4:40-49 (1991)
A33	Tomlinson et al., "Controllable gene therapy pharmaceuticals of non-viral gene delivery systems," <i>J. Controlled Release</i> 39:357-372 (1996)
A34	Uglea, C.V. et al., "Medical Applications of Synthetic Oligomers," <i>Polymeric Biomaterials</i> 725-747 (1993)
EXAMINER:	
DATE CONSIDERED:	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

TECHNOLOGY CENTER R3700

JUN 12 2002